Semaglutide vs Retatrutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
Semaglutide is a GLP-1 receptor agonist, a peptide engineered to mimic the natural gut hormone GLP-1 but with a roughly week-long half-life so it can be dosed once weekly. It is FDA-approved and sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management, with cardiovascular benefit also on the label. This is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides.
Also: LY3437943, Triple G
Retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - GIP, GLP-1, and glucagon - earning it the nickname triple-G agonist. In phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 TRIUMPH-1 trial Lilly reported 28.3 percent at 12 mg over 80 weeks. It is investigational, made by Eli Lilly, and not FDA approved; Lilly plans to file with the FDA in the first quarter of 2027. Because it is not an approved drug, FDA says it cannot be legally compounded.
Key Comparison Insights
- Semaglutide is FDA approved, while Retatrutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide has stronger research evidence (FDA Approved) compared to Retatrutide (Human Trials).
- Both are GLP-1 class medications compared in weight management studies.
Detailed Comparison
| Attribute | Semaglutide | Retatrutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide latches onto the GLP-1 receptor, the same receptor your own GLP-1 hormone uses after a meal. Activating it tells the pancreas to release more insulin when blood sugar is high, dials down glucagon (the hormone that raises blood sugar), and slows how fast the stomach empties, so you feel full longer. It also acts on appetite centers in the hypothalamus, which is the main reason it reduces hunger and drives weight loss. The molecule was modified with a fatty-acid chain that binds to albumin in the blood, which is the trick that stretches its half-life to about 160 hours and allows once-weekly injection. | Retatrutide combines three hormone signals into one molecule. The GLP-1 component curbs appetite and slows stomach emptying, the GIP component supports insulin response and may improve how fat tissue handles nutrients, and the added glucagon receptor activity is the novel piece: glucagon can increase energy expenditure and fat burning in the liver. The idea is that two arms cut how much you eat while the third raises how much you burn, which is why retatrutide is thought to push weight loss further than GLP-1-only drugs like semaglutide or even the dual GIP/GLP-1 agonist tirzepatide. The exact contribution of each receptor in humans is still being worked out, so consider the glucagon-driven energy-expenditure story a strong hypothesis rather than fully nailed down. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 4-12 mg weekly Once weekly, same day each week |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Morning, same day each week | Morning, same day each week |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The clinical evidence is extensive and high quality. The SUSTAIN program established blood-sugar control in type 2 diabetes, and SUSTAIN 6 showed a reduction in cardiovascular events. For obesity, the landmark STEP 1 trial (New England Journal of Medicine, 2021) randomized nearly 2,000 adults without diabetes and found mean weight loss of 14.9% at 68 weeks on semaglutide 2.4 mg versus 2.4% on placebo. In the head-to-head STEP 8 trial it beat liraglutide (15.8% vs 6.4%). The weight tends to come back after stopping: in the STEP 1 extension, people regained about two-thirds of the lost weight within a year off the drug. The SELECT trial (17,604 adults with heart disease and overweight or obesity but no diabetes) cut major cardiovascular events by 20%, which is the basis of Wegovy's cardiovascular indication (March 2024), and the FLOW trial underpins the kidney indication. Common side effects are gastrointestinal (nausea, vomiting, constipation), usually worst during dose escalation. Oral versions are approved too. Unlike most peptides discussed in research circles, semaglutide is a fully approved medicine with a deep, published evidence base. | The first big human evidence was the phase 2 trial by Jastreboff and colleagues (New England Journal of Medicine, 2023), which randomized 338 adults with obesity (without type 2 diabetes) over 48 weeks. Mean weight reduction reached about 24 percent at the 12 mg dose, and weight loss had not clearly plateaued by week 48. In a liver-fat substudy of 98 participants, liver fat dropped by about 81 to 82 percent at the 8 and 12 mg doses by week 24. Phase 3 has since read out: in TRIUMPH-1, Lilly reported mean weight loss of 19.0, 25.9 and 28.3 percent at 4, 9 and 12 mg over 80 weeks versus 2.2 percent on placebo (efficacy estimand, which assumes people stayed on the drug; analyses counting everyone randomized come out a few points lower). TRIUMPH-2 (type 2 diabetes plus obesity) reached about 20.8 percent at 12 mg, and TRIUMPH-3 (severe obesity plus heart disease) about 22.6 percent. Side effects were dominated by dose-dependent gastrointestinal issues like nausea, vomiting, and diarrhea, plus a dysesthesia (skin sensitivity) signal at the top dose. Retatrutide sold outside of trials is not an approved, quality-controlled medicine. |
Frequently Asked Questions: Semaglutide vs Retatrutide
What is the difference between Semaglutide and Retatrutide?
Semaglutide is a weight loss peptide that semaglutide is a glp-1 receptor agonist, a peptide engineered to mimic the natural gut hormone glp-1 but with a roughly week-long half-life so it can be dosed once weekly. it is fda-approved and sold as ozempic and rybelsus for type 2 diabetes and as wegovy for chronic weight management, with cardiovascular benefit also on the label. this is one of the most rigorously tested peptides in existence, backed by large randomized trials, so the evidence here is in a completely different league from research-only peptides. Retatrutide is a weight loss peptide that retatrutide is the heavy hitter of the new weight-loss drugs: a once-weekly injectable peptide that hits three receptors at once - gip, glp-1, and glucagon - earning it the nickname triple-g agonist. in phase 2 it produced about 24 percent weight loss at the top dose, and in the phase 3 triumph-1 trial lilly reported 28.3 percent at 12 mg over 80 weeks. it is investigational, made by eli lilly, and not fda approved; lilly plans to file with the fda in the first quarter of 2027. because it is not an approved drug, fda says it cannot be legally compounded. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Retatrutide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Retatrutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Retatrutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Retatrutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.